Clinical Trials
17 trialsNCT07343960 2026-05-20
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
Phase 1 Recruiting
NCT03616587 2026-04-30
SERENA-1
AstraZeneca
Phase 1 Active not recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07241065 2026-04-15
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
AstraZeneca
Phase 1 Recruiting
NCT07088913 2026-03-03
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT02208375 2025-12-31
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed
NCT02338622 2024-09-26
ComPAKT
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT04958226 2024-01-25
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT03310541 2023-05-06
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04742036 2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1 Completed
NCT04087174 2022-07-13
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
AstraZeneca
Phase 1 Completed
NCT04944771 2022-05-09
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT04712396 2021-04-09
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
AstraZeneca
Phase 1 Completed
NCT01895946 2016-05-25
OAK
AstraZeneca
Phase 1 Completed
NCT01353781 2016-04-26
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed